A Phase 2, Multicenter, Open-label, Proof-of-concept Study With Safety Run-in to Evaluate the Safety, Pharmacokinetics, and Efficacy of VP-315 in Adult Subjects With Basal Cell Carcinoma
Latest Information Update: 23 Aug 2024
At a glance
- Drugs Ruxotemitide (Primary)
- Indications Basal cell cancer
- Focus Adverse reactions; Proof of concept; Registrational; Therapeutic Use
- Sponsors Verrica Pharmaceuticals
- 14 Aug 2024 According to a Lytix Biopharma media release, the positive results in patients with basal cell carcinoma from this trial, are encouraging for companys new Phase II study at the Radium Hospital, Norway.
- 14 Aug 2024 According to a Verrica Pharmaceuticals media release, company expects to finalize the phase II study in H1 2025 and plans to request an End-of-phase 2 meeting with the Food and Drug Administration (FDA) to determine next steps for the development of VP-315 for the treatment of BCC in the first half of 2025.
- 14 Aug 2024 Preliminary positive results presented in a Lytix Biopharma media release.